- bladder cancer neoadjuvant treatment and organ preservation
- bladder cancer chemotherapy and radiotherapy
- testicular cancer: all aspects of treatment and follow-up
- prostate cancer: radiotherapy and general management including hormonal and chemotherapy
- intensity modulated, image guided and adaptive radiotherapy
Professor Huddart has both a Private and an NHS practice at The Royal Marsden. He joined The Royal Marsden as a Registrar in 1989 and was appointed Senior Lecturer and Honorary Consultant in Clinical Oncology at The Royal Marsden and The Institute of Cancer Research in 1995. He was made Reader in Urological Oncology in 2007 and Professor of Urological Cancer in 2015. He specialises in testicular, bladder and prostate cancer.
He has a major research interest in improving the management of bladder cancer, particularly to improve conservative treatment in patients with muscle invasive bladder cancer. A major focus of his current work is the technical development of radiotherapy, including research on intensity-modulated and image-guided radiotherapy and the application of new imaging techniques. This is alongside work in selecting patients for conservative treatment, use of neoadjuvant and concomitant therapies.
His second major research interests are in the management of testicular cancer with a focus on improving outcomes in high-risk disease, minimising toxicity in low-risk disease, work on survivorship issues and the genetics of testicular cancer.
Professor Huddart is a current member of the following national/International groups:
- NCRI Bladder Cancer localised and advanced sub-groups
- Co Chair of CT Rad workstream 3
- Trustee of British Uro-oncology group
- MaGic germ cell consortium
- IGCCCG working party
- ICRI bladder subgroup